Sanofi upgrades 2021 guidance after sales of Dupixent and diabetes products increase

France-based pharmaceutical company Sanofi reported progress on its top line and increasing sales of eczema treatment Dupixent and diabetes products in its quarterly report. The firm is therefore upgrading its guidance for the year.


Sanofi is upgrading its financial guidance for the rest of the year, now expecting growth in earnings per share of around 12 percent excluding currency fluctuations (at Constant Exchange Rates, CER). It previously expected growth of 6-9 percent.

The company reported the new guidance on Thursday when it released its Q2 report.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs